| Literature DB >> 23536790 |
Chantal M Morel1, Ngo Duc Thang, Annette Erhart, Nguyen Xuan Xa, Koen Peeters Grietens, Le Xuan Hung, Le Khan Thuan, Pham Van Ky, Nguyen Manh Hung, Marc Coosemans, Umberto D'Alessandro, Anne Mills.
Abstract
BACKGROUND: Despite much success in reducing the burden of malaria in Vietnam, pockets of malaria persist and eliminating them remains an important development goal. In central Vietnam, insecticide-treated hammocks have recently been introduced to help counter the disease in the highly forested, mountainous areas, where other measures have so far been unsuccessful. This study assesses the cost-effectiveness of using long-lasting insecticide-treated hammocks in this area. METHODS ANDEntities:
Mesh:
Substances:
Year: 2013 PMID: 23536790 PMCID: PMC3594234 DOI: 10.1371/journal.pone.0058205
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Programme, health system and household costs, unit costs and cost-effectiveness ($2012).
|
| |||
|
| |||
| Base hammock | 4.70 | ||
| Olyset netting | 5.88 | ||
| Sewing of netting | 0.76 | ||
| Transport | 0.42 | ||
| Total cost per LLIH | 11.76 | ||
|
| 22,139 | ||
|
| |||
| 2.1 Village level treatment | |||
|
| Cost per year | Cost per episode seen at this level of care | |
| Labour | 88 | 5.37 | |
| Diagnostic supplies | 1.13 | ||
| Treatment | 0.33 | ||
| total | 6.83 | ||
| 2.2 CHC level treatment | |||
|
| Cost per year | Cost per item | Cost per episode seen at this level of care |
| Building | 7385 | 2.63 | |
| Equipment | 595 | 1.69 | |
|
| |||
| Labour | 2687 | 18.76 | |
| Diagnostic supplies | 42.44 | 1.43 | |
| Treatment | 0.34 | ||
| Overheads | 25.64 | 0.21 | |
| total | 25.06 | ||
| 2.3 Hospital level treatment | |||
|
| Cost per year | Cost per item | Cost per episode seen at this level of care |
| Building | 1,477,140 | 11.47 | |
| Vehicle | 31,653 | 0.53 | |
| Equipment | 886,285 | 14.84 | |
|
| |||
| Fuel | 2,028 | 0.40 | |
| Labour | 627,785 | 125.44 | |
| Consumables | 18,464 | 5.40 | |
| Overheads | 221,350 | 44.24 | |
| total | 202.32 | ||
| 2.4 Total health systems cost per episode | |||
| Treatment seeking probabilities in base episode | Cost | Overall cost per average episode | |
| VHW (uncomplicated) | 0.6 | 6.83 | 4.10 |
| CHC (uncomplicated) | 0.3976 | 25.04 | 9.96 |
| Hospital | 202.32 | ||
| CHC+Hospital (severe) | 0.0024 | 227.36 | 0.54 |
| total | 14.60 | ||
| 3. Household costs per average episode | |||
| Travel | 0.11 | ||
| Treatment | 0.68 | ||
| Indirect (productivity loss) | 13.58 | ||
| total | 14.37 | ||
| 4. Total costs and cost-effectiveness | |||
| Total annualized, discounted programme costs (including 7000 LLIH) | 22,139 | ||
| Total household costs per episode | 14.37 | ||
| Total health systems cost per episode | 14.60 | ||
| Episodes averted through LLIH per year | 143 | ||
| Gross programme cost per episode averted | 155.18 | ||
| Total resource savings achieved per year | 4,143 | ||
| Total cost for LLIH programme per year (net of all resource savings) | 17,996 | ||
| Net societal cost per episode averted | 126 | ||
| Net societal cost per episode averted net of household savings | 140 | ||
| Net societal cost per episode averted net of all resource savings | 155 | ||
Sensitivity analysis.
| Base case value | Testing value | Cost per case averted using testing value | Deviation from base case cost per episode averted | Justification of use of testing value | |
| Cost per base hammock (USD) | 4.70 | (×0.5) | 94.89 | −25% | a. (see bottom of table) |
| (×2) | 187.78 | 49% | |||
| (×3) | 249.71 | 98% | |||
| Cost of transport per net (USD) | 0.42 | (×0.5) | 123.14 | −2% | b. |
| (×2) | 131.27 | 4% | |||
| (×3) | 136.69 | 9% | |||
| Indirect cost per household per episode (USD) | 13.58 | (×0.5) | 132.64 | 5% | c. |
| (×2) | 112.28 | −11% | |||
| (×3) | 98.69 | −22% | |||
| Overall % of cases that are severe | 0.24% | 0% | 107.48 | 0% | d. |
| 2% | 103.73 | −3% | |||
| 10% | 89.70 | −16% | |||
| Cases averted in individuals >10 years of age | 70% | 50% | 108.43 | 1% | e. |
| 30% | 109.81 | 3% | |||
| 10% | 111.19 | 4% | |||
| Cases in study area seen at the village level | 60% | 40% | 107.31 | 0% | f. |
| 80% | 106.8 | 0% | |||
| Useful life of LLIH (years) | 4 | 2 | 231.18 | g. | |
| 5 | 82.25 | −23% | |||
| Discount rate | 3% | 0% | 98.21 | −8% | h. |
| 5% | 113.05 | 6% |
The LLIH were manufactured specifically for this project. For possible transferability of findings the base case values should therefore be considered point estimates for a variable with potential high variability. Base case estimates were halved, doubled, and tripled.
Indirect costs of malaria to household (from Morel et al. 2008) were calculated from the estimated productivity loss to the patient’s household due to illness. As productivity is a function of weather and other factors, it may vary considerably from year to year.
Evidence on severity of cases in the base case was drawn from years when extremely few severe episodes were detected, which may represent an exception rather than the norm. Higher levels were used in the sensitivity analysis to represent slightly higher (2%), the estimate used in Morel et al. 2008 based on a large passive case detection study47, and much higher (10%) estimates.
The base case assumes LLIH protect patients at random, independently of their age. However, episodes averted through use of LLIH may be age dependent 47 given that age groups may stay in the forest for different amounts of time and undertake activities which expose them to varying degrees to the malaria vector. The sensitivity analysis tests for an age-effect in either direction, protection largely in adults and largely in children.
At the time of study, the VHW programme was just getting underway. Over time it could be expected that more malaria patients will come to understand that the VHW is trained to test for and treat malaria. This may increase the treatment seeking activity at the village level.
Prior to trial commencement the understanding was that LLIH life span would be between 3 and 5 years; however researchers considered at the end of the trial that it might in fact be closer to 2 years (the actual life span could not be measured given that the effectiveness trial lasted 2 years only).
As per common practice.